Business Wire

ONCODNA

14.2.2020 11:02:06 CET | Business Wire | Press release

Share
OncoDNA Closes Successful Series B Investment Round

OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.

The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank with the significant support of SFPI-FPIM. Historical shareholders together with CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW have also participated. This represents another landmark achievement after the €8 million Series A fundraising closed in September 2016.

OncoDNA is now maximizing the fast and proper rollout of its oncology clinical decision support software OncoKDM® with the objective of becoming the European leader in oncogenomic data interpretation and reporting to further support molecular laboratories, healthcare professionals and the pharma industry in their daily research and clinical practice.

Jean-Pol Detiffe, Founder & Chief Executive Officer at OncoDNA : “We are delighted to have successfully raised sufficient new capital from such quality investors who will enable us to grow and increase our support to oncologists and cancer patients with our data driven solutions. OncoDNA is already positioned as the European champion for cancer precision medicine as we built a worldwide network of more than several thousand oncologists. Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors.”

Guy Geldhof, Partner at Vesalius Biocapital III S.C.A. SICAR said: “We are excited about co-leading the Series B investment in OncoDNA. It is thrilling to work with a team that has both world class experience in genomic molecular profiling and a strong desire to serve patients by offering best-in-class support to oncology professionals. We are confident OncoDNA will accelerate the development and commercialization of its valuable new solutions, especially through closer collaborations with the biopharma industry, with the final objective of contributing to better healthcare .”

Robert Schier, Partner at Swisscanto (CH) Private Equity Switzerland Growth I KmGK added: “OncoDNA has grown significantly over the past years and are continuing to add the necessary clinical expertise and know-how to act upon its mission. Its disruptive vision and highly integrated market approach make it to be the perfect candidate to rapidly become the European leader in oncology big data. We are delighted to partner with OncoDNA as we firmly believe the company contributes to both a more sustainable healthcare system and improved patient health outcomes.”

“Considering our important investment in OncoDNA, alongside players like Vesalius Biocapital III and Swisscanto, we are convinced that the company has all the necessary means at a key moment of its development to successfully carry out appropriate projects to assist and support oncologists in prescribing the most optimal therapeutic treatments to patients. We are happy to count on the support of our colleagues from SRIW and Sambrinvest as historical stakeholders” concluded François Fontaine, at SFPI-FPIM.

OncoDNA

OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities who would like to reach the same level of expertise, we provide them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, employs 50 employees in 4 countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.

www.oncodna.com

www.vesaliusbiocapital-3.com

www.swisscanto.ch

www.sfpi-fpim.be/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press release

Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The

Semiconductor Companies Get Tough on AI Investment, but Measuring Returns Remains a Challenge9.11.2026 12:03:00 CET | Press release

HTEC research finds semiconductor companies are ahead in scaling AI, yet fragmented measurement is making it harder to connect engineering gains to business outcomes HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109039341/en/ HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. Nearly half (48%) of semiconductor respondents describe their organizations as scaling AI or already AI-native, comp

GoFundMe Surpasses $50 Billion Raised, Celebrating the People Powering a Global Movement of Help9.11.2026 12:00:00 CET | Press release

The inaugural Kind 50 list celebrates the people behind the milestone – and how help brings people closer together GoFundMe today announced that its global community has surpassed $50 billion raised to help individuals and nonprofits around the world. More than 200 million people have donated through GoFundMe, and nearly 40% have given more than once, reflecting the extraordinary scale of people showing up for one another – and continuing to come back to help. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109255455/en/ Celebrating $50B raised on GoFundMe with The Kind 50. From showing up for a friend in need to mobilizing entire communities, The Kind 50 celebrates people and organizations whose acts of kindness – on and off GoFundMe – made an impact over the past year and inspired others to help. To mark the milestone, GoFundMe is introducing The Kind 50, a celebration of the internet’s kindest people. The inaugural list

Prodalim Reports Q3 2026 Results, with Growth in its Specialty Ingredients & Solutions Business and Solos Activity Net Profit and Cashflow from Operating Activities9.11.2026 11:18:00 CET | Press release

Group revenues for the quarter grew 7% reaching US$98.4 million.SIS revenues (Specialty Ingredients & Solutions) grew 30% in Q3 reaching US$20 million.Adjusted EBITDA1 for the SIS grew 37% reaching US$4.3 million, reflecting an adjusted EBITDA margin of 21.4%.Juice Solutions revenues grew 2% in the quarter to US$78 million, improvement in adjusted EBITDA margin to 11.0%.Group’s adjusted net profit grew 34% reaching US$4.2 million.Cashflow from operating activities in the quarter was strong, increasing to US$16.7 million.Last week, the Company announced a strategic acquisition, of BOK, a South African company that produces natural ingredients, high value grape based specialty using circular economy principles. Regulatory News: Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth across all key operating parameters, alongside an important strategic acquisition. We continue to make substantial investments in production i

Logistics Reply named a Leader in the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing9.11.2026 10:00:00 CET | Press release

Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail 2026 Vendor Assessment (doc #US53701926, October 2026) as well as in the IDC MarketScape: Worldwide Warehouse Management for Manufacturing 2026 Vendor Assessment (doc #US53013526, October 2026). The reports evaluate vendors based on strategy and product capabilities, looking at both quantitative and qualitative criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109197861/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing. LEA ReplyTM is Logistics Reply’s cloud-native warehouse

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye